These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38543861)

  • 1. Immunogenicity, Safety, and Efficacy of Influenza Vaccine in T2DM and T2DM with Chronic Kidney Disease.
    Heryaman H; Juli C; Nazir A; Syamsunarno MRAA; Yahaya BH; Turbawaty DK; Sari RM; Permana H; Supriyadi R; Atik N
    Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial.
    Chang YT; Ling TC; Cheng YY; Sun CY; Wu JL; Tai CH; Wang JR; Sung JM
    Vaccines (Basel); 2021 Feb; 9(3):. PubMed ID: 33669067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children.
    Soedjatmiko S; Medise BE; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Bachtiar NS; Sari RM
    Vaccine; 2018 Apr; 36(16):2126-2132. PubMed ID: 29551225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults.
    Fadlyana E; Dhamayanti M; Tarigan R; Prodjosoewojo S; Rahmadi AR; Sari RM; Rusmil K; Kartasasmita CB
    PLoS One; 2023; 18(8):e0281566. PubMed ID: 37616221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease.
    Li Y; Ma Y; An Z; Yue C; Wang Y; Liu Y; Yuan X; Zhang S; Shao M; Li C; Li K; Yin Z; Wang L; Wang H
    Hum Vaccin Immunother; 2021 Sep; 17(9):3131-3136. PubMed ID: 33984257
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial.
    Han SB; Rhim JW; Shin HJ; Lee SY; Kim HH; Kim JH; Lee KY; Ma SH; Park JS; Kim HM; Kim CS; Kim DH; Choi YY; Cha SH; Hong YJ; Kang JH
    Hum Vaccin Immunother; 2015; 11(5):1094-102. PubMed ID: 25875868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Influenza Vaccination on the Reduction of the Incidence of Chronic Kidney Disease and Dialysis in Patients with Type 2 Diabetes Mellitus.
    Sung LC; Chen CC; Liu SH; Chiu CC; Yang TY; Lin CH; Fan YA; Jian W; Lei MH; Yeh HT; Hsu MH; Hao WR; Liu JC
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M; Tarigan R; Fadlyana E; Prasetyo D; Amalia N; Rusmil VK; Sari RM; Bachtiar NS; Rusmil K; Kartasasmita CB
    Vaccine; 2020 Jan; 38(5):993-1000. PubMed ID: 31862195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
    Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
    Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
    Noh JY; Song JY; Choi WS; Lee J; Seo YB; Kwon YJ; Ko GJ; Cha DR; Kang YS; Lee YK; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of an inactivated trivalent split influenza virus vaccine in young children with recurrent wheezing.
    Bae EY; Choi UY; Kwon HJ; Jeong DC; Rhim JW; Ma SH; Lee KI; Kang JH
    Clin Vaccine Immunol; 2013 Jun; 20(6):811-7. PubMed ID: 23536692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
    Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Open-label Randomized Controlled Parallel-group Pilot Study Comparing the Immunogenicity of a Standard-, Double-, and Booster-dose Regimens of the 2014 Seasonal Trivalent Inactivated Influenza Vaccine in Kidney Transplant Recipients.
    Odongo FCA; Braga PE; Palacios R; Miraglia JL; Sartori AMC; Ibrahim KY; Lopes MH; Caiaffa-Filho HH; Timenetsky MDCST; Agena F; Fonseca de Azevedo LS; David-Neto E; Precioso AR; Pierrotti LC
    Transplantation; 2022 Jan; 106(1):210-220. PubMed ID: 33988337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
    Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR;
    Lancet; 2017 Aug; 390(10095):649-658. PubMed ID: 28666680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA; Ribeiro Dos Santos R; Jose Nunes M; Soni J; Li P; Jain VK; Ofori-Anyinam O
    Braz J Infect Dis; 2017; 21(1):63-70. PubMed ID: 27912069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary data on immunogenicity, safety and tolerability of trivalent inactivated influenza vaccine in children with inborn errors of metabolism at risk of decompensation.
    Esposito S; Salvini F; Menni F; Scala A; Salvatici E; Manzoni F; Riva E; Giovannini M; Principi N
    Vaccine; 2013 Oct; 31(45):5149-51. PubMed ID: 24012567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.